Nidan Laboratories And Healthcare Ltd. significantly lags behind its peers in key financial metrics, including growth, profitability, and efficiency. The analysis reveals that while some peers demonstrate strong profitability and growth trajectories, others are overvalued or financially risky. Overall, Nidan should be approached with caution, as it lacks essential financial metrics necessary for a robust investment case.

• • Nidan Laboratories shows no revenue growth, profit margins, or valuation metrics, indicating it is underperforming across the board.
• • Max Healthcare leads in profitability metrics, while Aster DM Healthcare presents an attractive valuation despite poor growth.
• • Apollo Hospitals and Narayana Hrudayalaya show strong returns and sustainable growth, positioning them well in the sector.